|
DK1848414T3
(da)
|
2005-02-03 |
2011-07-25 |
Gen Hospital Corp |
Fremgangsmåde til behandling af gefitinib-resistent cancer
|
|
AU2006311877A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth Llc |
Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
|
|
CA2833852C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
PL2300013T5
(pl)
|
2008-05-21 |
2025-04-28 |
Takeda Pharmaceutical Company Limited |
Pochodne fosforu jako inhibitor kinazy
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
SI2310011T1
(sl)
|
2008-06-17 |
2013-10-30 |
Wyeth Llc |
Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
|
|
TWI458721B
(zh)
*
|
2008-06-27 |
2014-11-01 |
Celgene Avilomics Res Inc |
雜芳基化合物及其用途
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
BRPI0916694B1
(pt)
|
2008-08-04 |
2021-06-08 |
Wyeth Llc |
uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
|
|
TW201024281A
(en)
*
|
2008-11-24 |
2010-07-01 |
Boehringer Ingelheim Int |
New compounds
|
|
AR074210A1
(es)
|
2008-11-24 |
2010-12-29 |
Boehringer Ingelheim Int |
Derivados de pirimidina como inhibidores de ptk2-quinasa
|
|
CA2755789C
(en)
|
2009-04-06 |
2016-01-19 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
EP2451445B1
(en)
|
2009-07-06 |
2019-04-03 |
Boehringer Ingelheim International GmbH |
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
|
US8466155B2
(en)
|
2009-10-02 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Pyrimidines
|
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
WO2011140338A1
(en)
*
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
|
HUE029196T2
(en)
*
|
2010-06-04 |
2017-02-28 |
Hoffmann La Roche |
Aminoprimidine derivatives as LRRK2 modulators
|
|
LT2585470T
(lt)
|
2010-06-23 |
2017-04-10 |
Hanmi Science Co., Ltd. |
Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
RU2013109393A
(ru)
|
2010-08-10 |
2014-09-20 |
Сэлджин Авиаломикс Ресеарч, Инк. |
Безилатная соль ингибитора втк
|
|
EP2635285B1
(en)
*
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CA2815858C
(en)
|
2010-11-01 |
2018-10-16 |
Celgene Avilomics Research, Inc. |
Heterocyclic compounds and uses thereof
|
|
BR112013011600B1
(pt)
|
2010-11-10 |
2022-01-11 |
Genentech, Inc |
Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
|
|
EP2637502B1
(en)
*
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
EP2646819A1
(en)
*
|
2010-11-30 |
2013-10-09 |
Genentech, Inc. |
Assays and biomarkers for lrrk2
|
|
PL2678332T3
(pl)
*
|
2011-02-25 |
2016-12-30 |
|
Pochodne diaminopirymidyny i sposoby ich wytwarzania
|
|
WO2012135801A1
(en)
*
|
2011-04-01 |
2012-10-04 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
WO2012143144A1
(en)
|
2011-04-21 |
2012-10-26 |
Origenis Gmbh |
Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
US8828391B2
(en)
*
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
LT2729173T
(lt)
|
2011-07-06 |
2016-10-10 |
Sykehuset Sorlandet Hf |
Egfr taikinių terapija
|
|
ES2548414T3
(es)
|
2011-07-08 |
2015-10-16 |
Novartis Ag |
Novedosos derivados de pirrolo pirimidina
|
|
ES2654177T3
(es)
|
2011-07-27 |
2018-02-12 |
Astrazeneca Ab |
Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
|
|
JP2014531449A
(ja)
*
|
2011-09-20 |
2014-11-27 |
セルゾーム リミティッド |
キナーゼ阻害剤としてのピラゾロ［４，３―ｃ］ピリジン誘導体
|
|
PE20141228A1
(es)
|
2011-09-22 |
2014-10-01 |
Pfizer |
Derivados de pirrolopirimidina y purina
|
|
CA2853498A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
CN103086982A
(zh)
*
|
2011-10-31 |
2013-05-08 |
上海壹志医药科技有限公司 |
嘧啶衍生物的盐
|
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
CA2852609C
(en)
*
|
2011-11-29 |
2020-03-10 |
F. Hoffmann-La Roche Ag |
Aminopyrimidine derivatives as lrrk2 modulators
|
|
AR089182A1
(es)
*
|
2011-11-29 |
2014-08-06 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de lrrk2
|
|
WO2013079505A1
(en)
*
|
2011-11-29 |
2013-06-06 |
F. Hoffmann-La Roche Ag |
Aminopyrimidine derivatives as lrrk2 modulators
|
|
KR20130076046A
(ko)
*
|
2011-12-28 |
2013-07-08 |
한미약품 주식회사 |
타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
CN110194748A
(zh)
*
|
2012-01-13 |
2019-09-03 |
艾森生物科学公司 |
杂环化合物及其作为抗癌药的用途
|
|
UA111010C2
(uk)
|
2012-01-17 |
2016-03-10 |
Астеллас Фарма Інк. |
Сполука піразинкарбоксаміду
|
|
RU2711077C9
(ru)
|
2012-03-15 |
2020-08-11 |
Селджен Кар Ллс |
Соли ингибитора киназы рецептора эпидермального фактора роста
|
|
BR112014022789B1
(pt)
*
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
|
|
LT2840080T
(lt)
*
|
2012-04-17 |
2018-02-12 |
Fujifilm Corporation |
Heterociklinis junginys, turintis azotą, arba jo druska
|
|
EP2844658B1
(en)
*
|
2012-05-03 |
2019-03-20 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
|
|
JP6469567B2
(ja)
*
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
|
|
KR20150027267A
(ko)
|
2012-06-29 |
2015-03-11 |
화이자 인코포레이티드 |
LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
|
|
US9505765B2
(en)
|
2012-07-26 |
2016-11-29 |
Confluence Life Sciences Inc. |
4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
|
|
KR102181365B1
(ko)
*
|
2012-08-06 |
2020-11-23 |
에이시아 바이오사이언시스 인코포레이티드. |
단백질 키나아제 억제제로서 새로운 피롤로피리미딘 화합물
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
CN104822663B
(zh)
*
|
2012-10-04 |
2017-03-08 |
犹他大学研究基金会 |
作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
|
|
JP6401169B2
(ja)
*
|
2012-10-04 |
2018-10-03 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
|
WO2014060112A1
(en)
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
|
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
US20150320861A1
(en)
*
|
2012-12-21 |
2015-11-12 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2953457B1
(en)
|
2013-02-08 |
2020-04-08 |
Celgene CAR LLC |
Erk inhibitors and uses thereof
|
|
US9346801B2
(en)
|
2013-03-01 |
2016-05-24 |
Amgen Inc. |
Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use
|
|
WO2014134308A1
(en)
*
|
2013-03-01 |
2014-09-04 |
Amgen Inc. |
Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and their use for the treatment of egfr / erbb2 related disorders
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
WO2014175370A1
(ja)
*
|
2013-04-25 |
2014-10-30 |
塩野義製薬株式会社 |
ピロリジン誘導体およびそれらを含有する医薬組成物
|
|
JP2016518408A
(ja)
*
|
2013-05-06 |
2016-06-23 |
クロヴィス・オンコロジー，インコーポレーテッド |
上皮増殖因子受容体キナーゼ阻害剤の塩
|
|
AU2014287209B2
(en)
|
2013-07-09 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
AU2014287016B2
(en)
*
|
2013-07-11 |
2018-11-01 |
Acea Biosciences Inc. |
Pyrimidine derivatives as kinase inhibitors
|
|
PL3027600T3
(pl)
|
2013-07-31 |
2022-08-08 |
Novartis Ag |
1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn
|
|
US10273224B2
(en)
|
2013-08-22 |
2019-04-30 |
Jubilant Biosys Limited |
Substituted pyrimidine compounds, compositions and medicinal applications thereof
|
|
US20170050936A1
(en)
|
2013-08-23 |
2017-02-23 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
CA2924362C
(en)
|
2013-09-18 |
2018-12-18 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Compound inhibiting activities of btk and/or jak3 kinases
|
|
US10125144B2
(en)
|
2013-10-07 |
2018-11-13 |
Kadmon Corporation, Llc |
Rho kinase inhibitors
|
|
EP3059227B1
(en)
|
2013-10-16 |
2019-06-26 |
FUJIFILM Corporation |
Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor
|
|
ES2676734T3
(es)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
UA115388C2
(uk)
*
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
MD4649C1
(ro)
*
|
2013-12-05 |
2020-04-30 |
Pfizer Inc. |
Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
|
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
WO2015103355A1
(en)
|
2014-01-01 |
2015-07-09 |
Medivation Technologies, Inc. |
Compounds and methods of use
|
|
US9815841B2
(en)
|
2014-01-29 |
2017-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds
|
|
CA2937431A1
(en)
|
2014-01-29 |
2015-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds
|
|
NO2718543T3
(enExample)
*
|
2014-02-04 |
2018-01-06 |
|
|
|
CN104860891B
(zh)
*
|
2014-02-25 |
2017-06-30 |
上海海雁医药科技有限公司 |
芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
置換されたヘテロアリール化合物および使用方法
|
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
US20170166598A1
(en)
*
|
2014-05-13 |
2017-06-15 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
CN104825455B
(zh)
*
|
2014-06-11 |
2017-08-15 |
中国科学院合肥物质科学研究院 |
依鲁替尼的用途
|
|
BR112016029662B1
(pt)
*
|
2014-06-19 |
2023-10-24 |
Takeda Pharmaceutical Company Limited |
COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
|
|
AU2015287969B2
(en)
*
|
2014-07-07 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
CN105315259B
(zh)
*
|
2014-07-29 |
2018-03-09 |
上海艾力斯医药科技有限公司 |
吡啶胺基嘧啶衍生物、其制备方法及应用
|
|
SG11201700777VA
(en)
|
2014-08-04 |
2017-02-27 |
Nuevolution As |
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
BR112017003186A2
(pt)
*
|
2014-08-22 |
2017-11-28 |
Fujifilm Corp |
composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos
|
|
CN105384694B
(zh)
*
|
2014-08-22 |
2020-09-04 |
四川海思科制药有限公司 |
一种取代的氨基嘧啶衍生物及其制备方法和药物用途
|
|
CN105384695B
(zh)
*
|
2014-08-22 |
2019-12-20 |
四川海思科制药有限公司 |
嘧啶衍生物及其制备方法和在医药上的应用
|
|
CN105461694B
(zh)
*
|
2014-09-27 |
2019-05-24 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
CN105524068B
(zh)
|
2014-09-30 |
2017-11-24 |
上海海雁医药科技有限公司 |
氮杂双环衍生物、其制法与医药上的用途
|
|
SI3205650T1
(sl)
*
|
2014-10-11 |
2021-10-29 |
Shanghai Hansoh Biomedical Co Ltd |
Zaviralec EGFR-ja in priprava ter uporaba le-tega
|
|
CN105503827B
(zh)
*
|
2014-10-11 |
2019-09-24 |
上海翰森生物医药科技有限公司 |
Egfr抑制剂及其制备方法和用途
|
|
HRP20250213T1
(hr)
|
2014-10-13 |
2025-04-25 |
Yuhan Corporation |
Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
|
|
WO2016060963A1
(en)
*
|
2014-10-14 |
2016-04-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
CN105085489B
(zh)
|
2014-11-05 |
2019-03-01 |
益方生物科技（上海）有限公司 |
嘧啶或吡啶类化合物、其制备方法和医药用途
|
|
SG11201704685TA
(en)
*
|
2014-12-11 |
2017-07-28 |
Beta Pharma Inc |
Substituted 2-anilinopyrimidine derivatives as egfr modulators
|
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
WO2016105525A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Novel pyrimidines as egfr inhibitors and methods of treating disorders
|
|
US9695200B2
(en)
|
2015-01-23 |
2017-07-04 |
Confluence Life Sciences, Inc. |
Heterocyclic ITK inhibitors for treating inflammation and cancer
|
|
WO2016130920A2
(en)
*
|
2015-02-13 |
2016-08-18 |
Dana-Farber Cancer Institute, Inc. |
Lrrk2 inhibitors and methods of making and using the same
|
|
CN107613769A
(zh)
*
|
2015-02-17 |
2018-01-19 |
润新生物公司 |
某些化学实体、组合物和方法
|
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
CN106146478B
(zh)
*
|
2015-04-10 |
2019-07-16 |
海南轩竹医药科技有限公司 |
三嗪衍生物类间变性淋巴瘤激酶抑制剂
|
|
WO2016175264A1
(ja)
*
|
2015-04-28 |
2016-11-03 |
カルナバイオサイエンス株式会社 |
抗マラリア活性を有する新規ヘテロアリール誘導体
|
|
CN106188029B
(zh)
*
|
2015-05-05 |
2018-09-18 |
山东轩竹医药科技有限公司 |
二并环类间变性淋巴瘤激酶抑制剂
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
JP6412471B2
(ja)
|
2015-07-15 |
2018-10-24 |
富士フイルム株式会社 |
含窒素複素環化合物の製造方法およびその中間体
|
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
JP6873980B2
(ja)
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
|
|
JP6767491B2
(ja)
*
|
2015-09-25 |
2020-10-14 |
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド |
Ｊａｋを阻害するための化合物及び方法
|
|
RU2018115334A
(ru)
|
2015-10-09 |
2019-11-11 |
Ацея Терапьютикс, Инк. |
Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
|
|
CN108137544B
(zh)
*
|
2015-12-10 |
2022-01-04 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
|
|
CN106905245B
(zh)
*
|
2015-12-23 |
2021-06-25 |
正大天晴药业集团股份有限公司 |
2,4-二取代的嘧啶类化合物
|
|
CN107098887B
(zh)
*
|
2016-02-22 |
2019-08-09 |
复旦大学 |
嘧啶类化合物
|
|
CN109952306A
(zh)
*
|
2016-04-19 |
2019-06-28 |
加利福尼亚大学董事会 |
ErbB抑制剂及其用途
|
|
WO2017204582A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof inhibiting growth of cancer cells and a stabilizer having low melting point
|
|
US10774064B2
(en)
|
2016-06-02 |
2020-09-15 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
|
EP3478687B1
(en)
*
|
2016-06-30 |
2024-03-20 |
Daewoong Pharmaceutical Co., Ltd. |
Pyrazolopyrimidine derivatives as kinase inhibitor
|
|
ES2846833T3
(es)
|
2016-07-18 |
2021-07-29 |
Janssen Pharmaceutica Nv |
Ligandos de obtención de imágenes de tau por PET
|
|
EP3492462B1
(en)
*
|
2016-07-26 |
2023-08-30 |
Shenzhen TargetRx, Inc. |
Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
|
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CN114149432B
(zh)
*
|
2016-09-30 |
2024-07-05 |
斯坦福国际研究院 |
用于癌症治疗的双重clk/cdk1抑制剂
|
|
KR102686957B1
(ko)
*
|
2016-11-08 |
2024-07-22 |
주식회사 대웅제약 |
신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
|
|
AU2017374992A1
(en)
|
2016-12-16 |
2019-06-20 |
Basf Se |
Pesticidal compounds
|
|
CU24560B1
(es)
|
2017-01-23 |
2021-12-08 |
Cadent Therapeutics Inc |
N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio
|
|
WO2018139883A1
(ko)
*
|
2017-01-26 |
2018-08-02 |
부광약품 주식회사 |
다중 표적 키나아제 저해제로서 융합피리미딘 유도체
|
|
JP7164203B2
(ja)
*
|
2017-02-08 |
2022-11-01 |
中国医▲薬▼研究▲開▼▲発▼中心有限公司 |
ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途
|
|
CN106916112B
(zh)
*
|
2017-03-02 |
2019-12-20 |
四川海思科制药有限公司 |
嘧啶衍生物及其制备方法和在医药上的应用
|
|
US11160280B2
(en)
|
2017-03-28 |
2021-11-02 |
Basf Se |
Pesticial compounds
|
|
CA3059072A1
(en)
|
2017-04-07 |
2018-10-11 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
KR102032418B1
(ko)
*
|
2017-06-15 |
2019-10-16 |
한국화학연구원 |
접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
TW201904577A
(zh)
|
2017-06-16 |
2019-02-01 |
美商貝達醫藥公司 |
N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
|
|
CN111683662B
(zh)
*
|
2017-08-28 |
2024-04-02 |
陈志宏 |
取代嘧啶类化合物及其药物组合物和治疗方法
|
|
JP2019062834A
(ja)
*
|
2017-10-03 |
2019-04-25 |
アークレイ株式会社 |
ヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異検出用プローブ、ヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異検出用キット、及びヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異の検出方法
|
|
UY37935A
(es)
*
|
2017-10-18 |
2020-03-31 |
Spectrum Pharmaceuticals Inc |
Inhibidores de tirosina quinasas de la familia de los egfr mutantes
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
UA127604C2
(uk)
|
2017-12-21 |
2023-11-01 |
Басф Се |
Пестицидні сполуки
|
|
KR102577242B1
(ko)
*
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
|
|
MX2020006799A
(es)
|
2017-12-28 |
2020-09-03 |
Daewoong Pharmaceutical Co Ltd |
Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
|
|
KR102577241B1
(ko)
*
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
|
|
MA51846A
(fr)
|
2018-02-15 |
2021-04-21 |
Nuvation Bio Inc |
Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
|
|
KR20190114910A
(ko)
*
|
2018-03-30 |
2019-10-10 |
한미약품 주식회사 |
상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
|
|
CN108530450B
(zh)
*
|
2018-05-03 |
2021-03-30 |
赖建智 |
具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
|
|
WO2019222093A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Ariad Pharmaceuticals, Inc. |
Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
|
|
AU2019295632B2
(en)
|
2018-06-25 |
2025-03-06 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
|
CN112601742A
(zh)
*
|
2018-06-30 |
2021-04-02 |
北京生命科学研究所 |
组织蛋白酶c抑制剂
|
|
EP3613738A1
(en)
*
|
2018-08-23 |
2020-02-26 |
Lead Discovery Center GmbH |
4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
|
|
KR102328682B1
(ko)
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
|
EP3849538A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US20200115389A1
(en)
|
2018-09-18 |
2020-04-16 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
|
EP3856349A1
(en)
*
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
EP3866798A4
(en)
*
|
2018-10-15 |
2022-07-13 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
|
|
AU2019366312B2
(en)
|
2018-10-22 |
2025-04-24 |
Novartis Ag |
Crystalline forms of potassium channel modulators
|
|
EP3643705A1
(en)
|
2018-10-24 |
2020-04-29 |
Basf Se |
Pesticidal compounds
|
|
CN109265469A
(zh)
*
|
2018-11-12 |
2019-01-25 |
大连医科大学附属第医院 |
嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途
|
|
JP7660063B2
(ja)
|
2018-12-28 |
2025-04-10 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
|
|
CN111393377B
(zh)
*
|
2019-01-02 |
2022-04-05 |
四川大学华西医院 |
具有抗癌作用的氘代嘧啶衍生物
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
KR20210142154A
(ko)
|
2019-03-21 |
2021-11-24 |
옹쎄오 |
암 치료를 위한 키나제 억제제와 조합된 dbait 분자
|
|
MX2021011810A
(es)
|
2019-03-29 |
2021-10-26 |
Astrazeneca Ab |
Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US20220296595A1
(en)
|
2019-05-05 |
2022-09-22 |
Qilu Regor Therapeutics Inc. |
Cdk inhibitors
|
|
WO2020245208A1
(en)
|
2019-06-04 |
2020-12-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
|
|
US12365664B2
(en)
|
2019-06-20 |
2025-07-22 |
Dana-Farber Cancer Institute, Inc. |
Small molecule inhibitors of SRC tyrosine kinase
|
|
BR112021025764A2
(pt)
*
|
2019-06-20 |
2022-02-01 |
Oncobix Co Ltd |
Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
|
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
EP3766879A1
(en)
|
2019-07-19 |
2021-01-20 |
Basf Se |
Pesticidal pyrazole derivatives
|
|
KR102470980B1
(ko)
*
|
2019-07-26 |
2022-11-25 |
차이나 리소시즈 파마수티컬 홀딩스 컴퍼니 리미티드 |
Egfr 및 erbb2에 작용하는 피리미딘계 화합물
|
|
BR112022002698A2
(pt)
|
2019-08-14 |
2022-07-19 |
Incyte Corp |
Compostos de imidazolil pirimidinilamina como inibidores de cdk2
|
|
MX2022004390A
(es)
|
2019-10-11 |
2022-08-08 |
Incyte Corp |
Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
CN111057021B
(zh)
*
|
2019-12-11 |
2023-05-23 |
中国药科大学 |
均三嗪类化合物及其制备方法和用途
|
|
JP2021098692A
(ja)
|
2019-12-20 |
2021-07-01 |
ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ |
核内受容体に対して活性の化合物
|
|
US11685727B2
(en)
|
2019-12-20 |
2023-06-27 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
CA3163007A1
(en)
|
2019-12-23 |
2021-07-01 |
John Emmerson Campbell |
Inhibitors of mutant forms of egfr
|
|
US12441707B2
(en)
|
2019-12-30 |
2025-10-14 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
CN115023428B
(zh)
*
|
2020-01-21 |
2025-04-08 |
江苏先声药业有限公司 |
嘧啶并吡咯类化合物
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
JP7713954B2
(ja)
|
2020-03-31 |
2025-07-28 |
ヌエヴォリューション・アクティーゼルスカブ |
核内受容体に対して活性な化合物
|
|
MX2022012260A
(es)
|
2020-03-31 |
2022-11-30 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
CN111848631B
(zh)
*
|
2020-08-28 |
2022-04-19 |
四川大学华西医院 |
一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
|
|
TW202212331A
(zh)
*
|
2020-09-22 |
2022-04-01 |
英屬開曼群島商百濟神州有限公司 |
作為ｅｇｆｒ抑製劑之吲哚啉化合物及衍生物
|
|
EP4301360A4
(en)
*
|
2021-03-02 |
2025-05-28 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
KR20220128590A
(ko)
*
|
2021-03-11 |
2022-09-21 |
주식회사 온코빅스 |
암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체
|
|
WO2022199599A1
(zh)
*
|
2021-03-23 |
2022-09-29 |
凯复(苏州)生物医药有限公司 |
丙烯酰基取代的化合物、包含其的药物组合物及其用途
|
|
CN116670127A
(zh)
*
|
2021-03-30 |
2023-08-29 |
贝达药业股份有限公司 |
Egfr抑制剂及其组合物和用途
|
|
WO2022206795A1
(en)
*
|
2021-04-02 |
2022-10-06 |
Taizhou Eoc Pharma Co., Ltd. |
A cyclin-dependent kinase inhibitor
|
|
CN117321036A
(zh)
*
|
2021-04-30 |
2023-12-29 |
成都安泰康赛生物科技有限公司 |
具有抗癌活性的苯基-o-喹啉、喹唑啉、噻吩并吡啶、噻吩并嘧啶、吡咯并吡啶、吡咯并嘧啶化合物
|
|
TW202317126A
(zh)
|
2021-06-15 |
2023-05-01 |
美商建南德克公司 |
Ｅｇｆｒ抑制劑和ｐｅｒｋ活化劑組合療法
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
CN113582995B
(zh)
*
|
2021-08-17 |
2022-08-16 |
西安交通大学 |
9-位含有丙烯酰氨基片段的-9h-嘌呤类化合物及其盐和应用
|
|
WO2023046128A1
(en)
*
|
2021-09-27 |
2023-03-30 |
Taizhou Eoc Pharma Co., Ltd. |
A cyclin-dependent kinase inhibitor
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
TW202333667A
(zh)
*
|
2021-12-13 |
2023-09-01 |
大陸商希格生科（深圳）有限公司 |
嘧啶或吡啶類衍生物及其醫藥用途
|
|
AU2022426300B2
(en)
*
|
2021-12-30 |
2025-09-18 |
Korea Research Institute Of Chemical Technology |
Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient
|
|
KR102847312B1
(ko)
*
|
2021-12-30 |
2025-08-19 |
한국화학연구원 |
피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
|
|
CN114957248B
(zh)
*
|
2022-05-09 |
2023-12-29 |
南开大学 |
一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
|
|
WO2024253416A1
(en)
*
|
2023-06-09 |
2024-12-12 |
Yuhan Corporation |
Pyrimidine/pyridine derivatives or salts thereof and pharmaceutical compositions comprising the same
|
|
CN119143806B
(zh)
*
|
2024-11-19 |
2025-03-11 |
四川大学华西医院 |
一种靶向egfr突变的二甲基氧膦取代的苯胺嘧啶衍生物、其制备方法、用途及其制成的药物
|